Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Author:

Merryman Reid W.1,Kim Haesook T.2,Zinzani Pier Luigi3,Carlo-Stella Carmelo45,Ansell Stephen M.6,Perales Miguel-Angel7,Avigdor Abraham8,Halwani Ahmad S.9,Houot Roch1011,Marchand Tony10,Dhedin Nathalie12,Lescaut Willy13,Thiebaut-Bertrand Anne14,François Sylvie15,Stamatoullas-Bastard Aspasia16,Rohrlich Pierre-Simon17,Labussière Wallet Hélène18,Castagna Luca45,Santoro Armando45,Bachanova Veronika19,Bresler Scott C.20,Srivastava Amitabh20,Kim Harim21,Pesek Emily1,Chammas Marie1,Reynolds Carol1,Ho Vincent T.1,Antin Joseph H.1,Ritz Jerome1,Soiffer Robert J.1,Armand Philippe1

Affiliation:

1. Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;

3. Institute of Hematology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy;

4. Humanitas Clinical & Research Center, Milan, Italy;

5. Department of Oncology and Hematology, University of Milan, Milan, Italy;

6. Mayo Clinic, Rochester, MN;

7. Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY;

8. Division of Hematology and Bone-Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel;

9. Huntsman Cancer Institute, Salt Lake City, UT;

10. Centre Hospitalier Universitaire (CHU) Rennes, Service Hématologie Clinique, Rennes, France;

11. INSERM, Rennes, France;

12. Hôpital Saint Louis, Service Hématologie Adolescents et Jeunes Adultes, Assistance Publique-Hôpitaux de Paris, Paris, France;

13. Centre Hospitalier Princesse Grace, Service Médecine Interne et Onco-Hématologie, Monaco, France;

14. CHU Grenoble, Clinique Universitaire d’Hématologie, Grenoble, France;

15. CHU Angers, Service Maladies du Sang, Angers, France;

16. Centre Henri Becquerel, Service Hématologie Clinique, Rouen, France;

17. CHU Nice, Service Hématologie et Onco-Hématologie Pédiatrique, Nice, France;

18. Hospices Civils de Lyon, Service d'Hématologie Clinique, Lyon, France;

19. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN;

20. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and

21. University College of Medicine, Seoul National University, Seoul, South Korea

Abstract

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference38 articles.

1. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired;Ahmadzadeh;Blood,2009

2. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;Dong;Nat Med,2002

3. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma;Ansell;N Engl J Med,2015

4. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online ahead of print 27 June 2016];Armand;J Clin Oncol,2016

5. Highlights of Prescribing Information - Nivolumab,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3